Kindeva Drug Delivery announced today that it appointed Denis Johnson as its new chief operating officer (COO). Johnson’s responsibilities include leading global operations for Kindeva’s manufacturing and R&D facilities across the U.S. and UK. The company expects him to facilitate the expansion and opening of the company’s new aseptic injectable fill-finish site in Bridgeton, Missouri. […]
Kindeva Drug Delivery
Kindeva Drug Delivery acquires nasal spray company Summit Biosciences
Kindeva Drug Delivery announced today that it acquired Summit Biosciences, an intranasal drug-delivery company. Summit, a drug delivery CDMO, brings a track record of innovation in the unit dose nasal spray market. Kindeva believes the acquisition enhances its existing drug delivery capabilities by adding a new platform. This new platform enhances its ability to serve […]
Kindeva wins £33M grant from UK to enhance drug-delivering inhalers
Kindeva Drug Delivery announced that it received a grant from a UK fund worth a $42.2 million (£33 million) investment. The grant from the UK Government’s Life Sciences Innovation Manufacturing Fund (LSIMF) aims to help Kindeva enhance inhaler manufacturing and sustainability. Funds improve Kindeva’s capability and capacity to manufacture the next generation of green pressurized […]
Kindeva Drug Delivery names new chief commercial officer
Kindeva Drug Delivery announced today that it appointed David Stevens as its global chief commercial officer (CCO). Stevens’ role includes spearheading the commercial, business development and R&D activities for Kindeva. He aims to ensure continued growth, expansion and innovation from the drug delivery device contract development and manufacturing organization (CDMO). “David brings a breadth of […]
Viatris, Kindeva win FDA approval for first generic version of Symbicort inhalation aerosol
Viatris (Nasdaq:VTRS) and Kindeva Drug Delivery announced today that the FDA approved its generic version of AstraZeneca’s Symbicort. In March 2021, the FDA granted tentative approval to Breyna (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol) — the first generic version of Symbicort. Today, the agency granted approval for the abbreviated new drug application (ANDA) for […]
Kindeva, Cambridge Healthcare Innovations to collaborate on dry-powder inhaler
Kindeva Drug Delivery and Cambridge Healthcare Innovations announced a collaboration to commercialize the latter’s dry-powder inhaler. St. Paul, Minn.-based Kindeva is set to use its product development, regulatory affairs and manufacturing capabilities to help develop and commercialize CHI’s Aeolus dry-powder inhaler (DPI) platform technology, according to a news release. Under the agreement, Kindeva will lead […]
Sandoz announces in-licensing of Kindeva respiratory inhalation aerosol
Sandoz announced that it is in-licensing the commercial distribution rights to a respiratory inhalation medicine from Kindeva Drug Delivery. Princeton, N.J.-based Sandoz in-licensed the rights to the brand and authorized generic of Proventil HFDA (albuterol sulfate) inhalation aerosol, which is immediately available to U.S. patients, according to a news release. Albuterol sulfate is used to […]
FDA tentatively approves first generic version of Symbicort inhalation aerosol
Viatris (NSDQ:VTRS) and Kindeva Drug Delivery announced today that the FDA granted tentative approval of the first generic version of Symbicort. Symbicort, an inhalation aerosol is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD). The drug had U.S. branded sales of $3.5 billion for the 12 months ended January 2021, according […]
Kindeva Drug Delivery launches as independent company from 3M
Kindeva Drug Delivery recently announced that it launched as an independent company, shedding its former 3M Drug Delivery Systems name. The formation of the independent company follows its acquisition by Altaris Capital Partners in a transaction that was worth $650 million. Through the acquisition, 3M will hold a 17% minority interest in Kindeva with Altaris. […]
